It is expected that the latest announcement by Net Savings Link Inc (OTCMKTS:NSAV) will help correct a February press release as well as a series of Twitter messages in line with NSAV’s relationship to the HeartRescue China Program.
Making amends about the mix up
It was just recently that NSAV outlined that Medtronic PLC was the lead sponsor of the project when in the real sense it needed to have outlined that the project’s lead sponsor was Medtronic Foundation. NSAV regrets its move and is sending out its apologies to both Medtronic Foundation and Medtronic PLC for the misleading mix up.
RTI International is the one leading the HeartRescue China program right now. Basically, RTI International is a US-based research institute and the other big name in this particular regard is the Shanghai based Vital Strategic Research Institute (VSRI) which is a subsidiary of NSAV.
Acute cardiovascular disease (CVD) becomes a major killer in China
Medtronic Foundation is the one funding and sponsoring the program which fundamentally seeks to improve access and quality of care for patients especially those that have been struggling with acute cardiovascular disease (CVD) over quite a long period of time in the republic of China.
Reports have it that over 1 million Chinese lose their lives every passing year from CVD of all types which at this point in time is the number one cause of death. VSRI, which happens to be NSAV’s subsidiary, is fundamentally a medical research firm pulling along with an elaborate history of expertise in global research and design of clinical trials.
In the past, VSRI has been able to strike business collaborations with pharmaceutical giants such as Bristol-Myers Squibb, Pfizer Inc (NYSE:PFE) and Eli Lilly.
The president of NSAV James Tilton opined, “We greatly appreciate the support that the Medtronic Foundation has provided to the HeartRescue Global Project. Without this support, there would be no project or opportunity to both save and improve the lives of Chinese people who suffer from acute cardiovascular disease.”
NSAV remains determined on its quest to revolutionize the beer industry and seems the partnership with German’s Beerchain technology will move quite a long way seeing it achieve its set goal.